BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective...
Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:...
BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately....
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenza Hantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines BOTHELL, Wash., May 26, 2026 (GLOBE...
Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohorts Highlighted CDI-988’s mechanism of action and clinical advancement at ICAR 2026 Granted FDA Fast Track designation for CDI-988, enabling the potential for an...
Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatment Fully enrolled first cohort is assessing the infectivity of the human challenge inoculum There are no approved treatments or vaccines for norovirus, the leading cause of acute gastroenteritis across...
FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic impact BOTHELL, Wash., April 02, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:...
Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the first oral antiviral candidate being developed for norovirus treatment and prevention No approved treatments or vaccines are available for norovirus infection, posing a significant unmet need and contributing to a global economic burden of $60 billion...
CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or vaccines are available for norovirus treatment and prevention, posing a significant unmet need and contributing to a global economic burden...